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approach
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Background: The great majority (60–80 %) of patients consulting specialist physicians for allergic respiratory disease 
are polysensitized and thus may be potentially clinically polyallergic. However, management approaches to allergen 
immunotherapy (AIT) in polysensitized and polyallergic patients are not standardized.
Methods: An international group of clinicians with in-depth expertise in AIT product development, clinical trials and 
clinical practice met to generate up-to-date, unambiguous, pragmatic guidance on AIT in polysensitized and polyal-
lergic patients. The guidance was developed after reviewing (1) the current stance of regulatory bodies and learned 
societies, (2) the literature data on single- and multi-AIT and (3) the members’ confirmed clinical experience with 
polysensitized patients.
Results: AIT is safe and effective in polysensitized and polyallergic patients, and should always be based on the 
identification of one or more clinically relevant allergens (based on the type and severity of symptoms, the duration of 
induced symptoms, the impact on quality of life and how difficult an allergen is to avoid). Single-AIT is recommended 
in polyallergic patients in whom one of the relevant allergens is nevertheless clearly responsible for the most intense 
and/or bothersome symptoms. Parallel 2-allergen immunotherapy or mixed 2-allergen immunotherapy is indicated 
in polyallergic patients in whom two causal relevant allergens have a marked clinical and QoL impact. In parallel 
2-allergen immunotherapy (whether subcutaneous or sublingual), high-quality, standardized, single-allergen formula-
tions must be administered with an interval of 30 min. Mixing of allergen extracts may be considered, as long as (1) 
the mixture is technically feasible, (2) the mixture is allowed from a regulatory standpoint, (3) the allergen doses are 
reduced in proportion to the number of components but are still at concentrations with demonstrated efficacy.
Conclusions: Physicians can prescribe AIT (preferably with high-quality, standardized, single-allergen formulations) 
with confidence in polysensitized and polyallergic patients by focusing on clinical/QoL relevance and safety.
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Background
Allergic respiratory disease is a global health problem 
that seriously affects the sufferers’ daily lives [1–6]. Indi-
viduals with clinical symptoms of IgE-driven allergic 
respiratory disease will have specific IgE to disease trig-
gering allergens as evidenced by skin prick tests (SPTs) 
or serum specific immunoglobulin E (ssIgE) assays. In 
surveys of the general population in Europe and the USA 
(performed with standard panels of allergens), polysensi-
tization is generally more prevalent than monosensitiza-
tion [7, 8]. In the first European Community Respiratory 
Health Survey, 12.8–25.3 % of the participants were poly-
sensitized [7]. Similarly, the National Health and Nutri-
tion Examination Surveys in the US found that 38.8 % of 
the participants were polysensitized [8].
Unsurprisingly, the great majority (60–80 %) of patients 
consulting allergists are polysensitized [9–12]. The preva-
lence of polysensitization increases with age [12–14], 
with 54 % in children under 11 years, 61.7 % in adoles-
cents and 64.8  % in adults (p  <  0.001) in the French 
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ODISSEE study, for example [12]. Longitudinal birth 
cohort studies (such as the Multicenter Allergy Study in 
Germany [15], the Manchester Asthma and Allergy Study 
in the UK [16, 17] and the Barn Allergy Milieu Stockholm 
Epidemiology study in Sweden [18]) have shown that pol-
ysensitization is a risk factor for the subsequent develop-
ment of allergic diseases in general and allergic asthma 
(AA) in particular. Polysensitization also impacts the 
clinical expression of the disease; the greater the num-
ber of sensitizations, the more severe the allergic disease 
[19]. Asthma is more likely to be associated with allergic 
rhinitis (AR) in polysensitized patients than in monosen-
sitized patients [12].
However, a polysensitized patient does not necessarily 
have polyallergy, whereas a polyallergic patient is nec-
essarily polysensitized. Polyallergy is defined as a docu-
mented, causal relationship between exposure to two or 
more specific, sensitizing allergens and the subsequent 
occurrence of relevant clinical symptoms of allergy 
(Table 1). Once polyallergy has been diagnosed, the phy-
sician’s next challenge is to decide (in collaboration with 
the patient) on a treatment strategy.
According to recent guidelines from the Interna-
tional Collaboration in Asthma, Allergy and Immunol-
ogy [20], allergen immunotherapy (AIT) is indicated 
for the treatment of moderate-to-severe intermittent or 
persistent symptoms of AR—especially in those who do 
not respond well to pharmacotherapy. However, in the 
recently updated WAO position paper [6] on sublin-
gual allergen immunotherapy (SLIT), failure of pharma-
cological treatment is not an essential prerequisite, and 
SLIT may be considered as an initial treatment for AR, 
in association with pharmacotherapy. We also consider 
that there are three additional indications for AIT: (a) the 
wish to avoid constant or long-term pharmacotherapy, 
(b) poor tolerability of symptomatic medications and (c) 
the wish to achieve a “cure” and possibly prevent disease 
progression (e.g. the development of new sensitizations 
and/or asthma) [21].
Methods
Clinical practice in the diagnosis of respiratory allergy 
and its management with AIT vary from one country to 
another. When AIT is prescribed, some allergists tend to 
treat the polyallergic patient with a single-allergen for-
mulation (using the most clinically relevant allergen), 
whereas others prefer to prescribe either a mixture of two 
or more allergen extracts or two or more separate aller-
gens [22]. Several publications have sought (to a lesser 
or greater extent) to address the management of the 
Table 1 Definitions
Term Definition
Allergen sources Allergen sources are allergens from the same homologous group (e.g. Dermatophagoides pteronyssinus and 
Dermatophagoides farinae)
Monosensitization Sensitization (according to standardized SPTs or ssIgE assays) to only one of the allergens tested in the patient 
to date. A single “allergen” is defined in allergists’ terms, i.e. grass pollen, tree pollen, house dust mite, cat 
dander (even though extracts of these extracts contain tens, hundreds or even thousands of different 
polypeptides)
Polysensitization Sensitization (according to standardized SPTs or ssIgE assays) to two or more allergens
Monoallergy Clinically confirmed allergy to a single, sensitizing allergen (i.e. a causal relationship between exposure to the 
sensitizing allergen and clinical allergy symptoms)
Polyallergy Clinically confirmed allergy to two or more sensitizing allergens (i.e. causal relationships between exposure to 
two or more sensitizing allergens and clinical allergy symptoms)
Homologous group A group of allergens with (1) comparable physicochemical and biological properties of the source material, 
(2) cross-reactivity/structural homology of the allergens, (3) identical formulation of the finished product, 
and (4) identical production process of the allergen extract and of the finished product, as defined by the 
European Medicines Agency
Allergen mixture A single formulation containing a mixture of several allergen sources (e.g. a grass pollen source mixed with a 
birch pollen source)
Single-allergen immunotherapy Administration of an allergen immunotherapy formulation containing a single allergen source
In the cases of sequential administration of two consecutive single-allergen immunotherapies.(e.g. 3 years of 
treatment with a house dust mite source, followed by 3 years of treatment with a grass pollen source) this 
does not constitute multi-allergen immunotherapy (see below)
Multi-allergen immunotherapy Administration of different allergen sources
Multi-allergen immunotherapy can be administered either in parallel (see below) or on a mixed formulation 
(see below)
Parallel multi-allergen immunotherapy The separate administration of two or more single-allergen immunotherapy formulations in parallel during the 
same course of treatment
Mixed multi-allergen immunotherapy The administration of an allergen mixture (i.e. a single formulation containing several allergen sources)
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polyallergic patient [11–13, 19, 23–27] and the princi-
ples governing production and quality issues when mix-
ing allergens in AIT preparations [27] but do not provide 
comprehensive, consensual, practical guidance.
Hence, we have designed a focussed, practice-based 
approach to the management of polyallergic patients. The 
objective of the present document is to provide physi-
cians with clear, up-to-date, unambiguous, pragmatic, 
clinically relevant guidance on their day-to-day prac-
tice. To do so, we constituted an international group of 
renowned clinicians with in-depth expertise in AIT prod-
uct development, clinical trials and clinical practice. The 
group developed consensual, unambiguous, pragmatic 
guidance on AIT in polysensitized monoallergic or poly-
allergic patients on the basis of (1) the literature data, (2) 
learned societies’ and regulatory agencies’ stances on the 
formulation and clinical use of multiple allergen immu-
notherapy (multi-AIT, such as a formulation containing 
two or more allergen extracts), and (3) the members’ con-
firmed clinical experience with polysensitized patients. 
The aim is to give clear-cut answers to the most frequent 
questions raised by practitioners and patients. However, 
these recommendations are not intended to replace a cli-
nician’s clinical judgement and must to be adapted to suit 
each individual patient.
Treatment of the polyallergic patient: a high‑priority topic
Before presenting our recommendations, we first con-
sider (1) the current stance of regulatory bodies and 
learned societies regarding multi-AIT, (2) the clinical trial 
evidence in favour of multi-AIT and (3) evidence from 
observational studies conducted in physicians’ practices 
or in the general population.
What is the regulatory authorities’ current stance on the 
composition of AIT formulations?
The European Medicines Agency (EMA) has published 
general guidelines for manufacturers on the preparation 
and composition of allergen extracts and mixtures of 
extracts [28]. We were unable to find any guidance from 
other agencies around the world, including the US Food 
and Drug Administration. The EMA guidelines are based 
on the principle of homologous groups, which nota-
bly takes account of the physicochemical and biological 
characteristics of allergen extracts (Table  2). The EMA 
recommends that allergists should mix non-related aller-
gens as little as possible and should not mix seasonal and 
perennial allergens or allergens with proteolytic activity 
(such as extracts of HDMs, moulds and insects) with-
out justification. Mixing allergens clearly has an impact 
on pharmaceutical parameters (stability and dosing) 
and clinical effects (optimal dose and safety). The EMA’s 
“homologous group” principal requires (1) description 
of the source materials’ physicochemical and biological 
properties, (2) definition of the allergens’ cross-reactiv-
ity and structural homology, (3) preparation of identical 
formulations of the final product, and (4) a guarantee 
that the extract’s production process does not vary. The 
homologous groups generally correspond to taxonomic 
families. Within a given homologous group, allergen 
extracts will be very similar in terms of the composi-
tion, the source material’s physicochemical and biological 
properties, the allergens’ structural homology (and thus 
cross-reactivity) and the production process [28]. Fur-
ther details on the rationale (based primarily on protein 
sequence data and cross-reactivity) for the six suggested 
homologous groups have been published (Table  2) [29]. 
The EMA document states that “to a limited extent, data 
on quality, safety and efficacy can be extrapolated from 
the representative source to other members of the homolo-
gous group”; for example, clinical data on birch allergen 
extracts can be extrapolated to other Betulaceae, such as 
the alder [28]. However, it is not possible to extrapolate 
efficacy results from one homologous group to another 
or from a homologous group to allergens that cannot 
be included in a homologous group; for example, clini-
cal data on birch cannot be extrapolated to cypress. The 
EMA insists that the number of allergen extracts in a 
mixture should be kept to a minimum (regardless of the 
homology/cross-reactivity of the individual extracts) and 
that the number and relative proportions of the individ-
ual active substances must be justified. Mixtures contain-
ing allergens that do not belong to the same homologous 
group must always be justified [28].
What are the current guidelines from learned societies on the 
management of polyallergic patients?
Recommendations from the GA2LEN/EAACI [23] clearly 
state that the number of sensitizations itself is less impor-
tant than the clinical relevance of each allergen. In fact, 
a personalised approach should be based on the iden-
tification of the clinically relevant allergen and should 
consider the type and severity of symptoms, the longest 
duration of induced symptoms over the year, the great-
est impact on quality of life (QoL) and how difficult an 
allergen is to avoid. When considering the composition 
of AIT formulations, the GA2LEN/EAACI guidelines 
do not recommend mixtures [23]. The Allergic Rhini-
tis in Asthma (ARIA) guidelines have continuously put 
forward the same principles [2–4]. The US AIT prac-
tice parameters have moved in the same direction [30]; 
the third update emphasizes that it is important to treat 
the patients only with relevant allergens. None of these 
guidelines, however, gives pragmatic recommendations 
on how clinicians can identify and manage polyallergic 
patients in their daily practice.
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Table 2 The homologous groups suggested by the EMA [28] and Lorenz et al. [29]
Homologous groups No homologous groups
Tree pollen
 1. Suggested homologous group: birch/fagales Non-grouped species: justification for mixing required
  Betula verrucosa = B. pendula* = B. alba European white birch Fagus sylvatica European beech
  Alnus glutinosa Alder Acer sp. Maple
 Carpinus betulus Hornbeam Platanus sp. Plane tree
  Corylus avellana Hazel Populus sp. Poplar
  Quercus alba Oak Robinia pseudoacacia False acacia, locust tree
  Castanea sativa Sweet chestnut Salix sp. Sallow/willow
Tilia sp. Lime
Ulmus sp. Elm
Cryptomeria japonica Japanese cedar
 2. Suggested homologous group: Oleaceae
  Olea europaea Olive
  Fraxinus excelsior Ash
  Ligustrum vulgare Privet
  Syringa vulgaris Lilac
 3. Suggested homologous group: Cupressaceae
  Juniperus sp. Juniper
  Cupressus sp. Cypress
Grass and cereal pollen
 4. Suggested homologous group: sweet grasses, the Poaceae (Gramineae) family,  
Pooideae subfamily
Non-grouped species: justification for mixing required
  Anthoxanthum odoratum Sweet vernal grass Cynodon dactylon Bermuda grass
  Avena sativa Oat Cynosurus cristatus Dogstail
  Dactylis glomerata Orchard grass/cocksfoot
  Festuca sp. Meadow fescue
  Holcus lanatus Velvet grass/Yorkshire fog
  Hordeum vulgare Barley
  Lolium perenne Perennial ryegrass
  Phleum pratense Timothy grass
  Poa pratensis Kentucky bluegrass
  Secale cereale Cultivated rye
  Triticum aestivum Cultivated wheat
 Additional Pooideae grass species, with reservations:
  Agropyron sp. Couch grass/crested wheatgrass
  Agrostis sp. Bent grass
  Alopecurus pratensis Meadow foxtail
  Arrhenatherum elatius False oat
  Bromus sp. Brome grass
Weed pollen
 5. Suggested homologous group: weed pollen species Non-grouped species: justification for mixing required
  Ambrosia artemisiifolia, Ambrosia trifida Ragweed Plantago sp. Plantain
  Artemisia vulgaris Mugwort
  Parietaria judaica, Parietaria officinalis Pellitory
MITES
 6. Suggested homologous group: house dust mites of the Dermatophagoides genus Non-grouped species: justification for mixing required
  Dermatophagoides pteronyssinus European house dust mite Acarus siro Flour mite
  Dermatophagoides farinae American house dust mite Glycyphagus domesticus House mite
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What is the clinical trial evidence for the efficacy and safety 
of multi‑AIT in polyallergic patients?
Few well-designed, double-blinded, placebo-controlled 
studies have evaluated treatment with multi-allergen 
formulations [24, 31–34]. Accordingly, most meta-anal-
yses published to date have evaluated AIT formulations 
containing a single allergen or several cross-reac-
tive allergens, and have urged caution with regard to 
multi-AIT. However, multi-AIT is common practice 
in the majority of allergists’ practices in the USA and 
in 20–40  % of the prescriptions in Europe [22]. This 
approach needs more supporting data from large clini-
cal trials before it can be validated as a treatment option 
in polyallergic patients [23, 31]. Although some clinical 
studies of multi-AIT have clearly demonstrated efficacy, 
the thousands of different mixtures used worldwide 
have not been sufficiently investigated. A review by Nel-
son identified 13 studies (published between 1965 and 
2007) in which two or more unrelated allergens were 
simultaneously administered as subcutaneous allergen 
immunotherapy (SCIT, 11 studies) or as SLIT (two stud-
ies) [32]. Nelson concluded that sublingual or subcuta-
neous administration of two simultaneous extracts was 
effective, on the basis of four studies reporting greater 
efficacy than placebo or much the same efficacy as 
single-AIT. Only seven of the trials were double-blind, 
placebo-controlled, randomized trials; it is obvious that 
most of these would not meet current standards for piv-
otal trials for regulatory approval.
What is the real‑life evidence for the efficacy and safety of AIT 
in polyallergic patients?
“Real-life” clinical practice in the diagnosis of respiratory 
allergy and its management with AIT varies from one 
country to another. When AIT is prescribed, some aller-
gists tend to treat the polyallergic patient with a single-
allergen formulation (using the most clinically relevant 
allergen), whereas others prescribe either a mixture of 
two or more allergen extracts or two or more separate 
allergen extracts. Real-life observational and post-mar-
keting studies show that AIT is safe and effective in poly-
allergic patients. Although very few observational surveys 
have been performed in allergists’ practices in Europe, 
the published data are very instructive. In a French study 
of 2434 polysensitized patients [35] reported that AIT 
was prescribed to 84.3  % of the patients. Of those who 
received AIT, 72.5 % were receiving a single formulation. 
When a single formulation was used, it was usually a sin-
gle extract (in 86 % of cases) or, less frequently, a mixture 
of two allergen extracts (12.8 %) or three or more extracts 
(1.1  %). For patients receiving two AIT formulations, 
each was almost always a single-allergen extract (in 97 % 
of these cases). Furthermore, the results of two open, 
prospective, observational studies in Germany demon-
strated that (1) polyallergic patients benefited as much 
from 300IR SLIT birch as monoallergic patients did and 
(2) in polyallergic patients treated with a 5-grass pollen 
extract, tolerability and symptom relief did not depend 
on the concomitant use of other allergen extracts [36, 37].
Table 2 continued
Homologous groups No homologous groups
Lepidoglyphus destructor Storage mite
Thyreophagus entomophagus Flour mite
Tyrophagus putrescentiae Storage mite
Insect venoms Non-grouped species: justification for mixing required
 No homologous groups All species
Allergen extracts derived from vertebrates (extracts such as animal epithelia,  
hair, dander)
Non-grouped species: justification for mixing required
 No homologous groups Canis familiaris Dog
Felis domesticus Cat






Moulds Non-grouped species: justification for mixing required
All species
 No homologous groups In case of justification of grouping of mould species,  
special emphasis on similar stability is necessary
Page 6 of 13Demoly et al. Allergy Asthma Clin Immunol  (2016) 12:2 
Ciprandi et  al. prospectively evaluated a group of 
87 adult patients (mean  ±  standard deviation age: 
29.7 ± 10.8) with AR and/or mild-to-moderate AA [38]. 
The mean number of sensitizations per patient was 3.5, 
and the most frequent sensitizing allergens were grass 
pollen (64.4  %), house dust mites (HDMs) (46  %) and 
Parietaria pollen (36.8  %). Fifty-nine patients (67.8  %) 
were treated with single-allergen SLIT and 28 (32.2  %) 
were treated with 2-allergen SLIT. Importantly, there 
was no difference in the clinical outcomes (symptom 
severity, rhinitis classification and QoL) between these 
two treatment groups. Similar results were found in 51 
polysensitized children (mean age: 11.8) with AR and/or 
mild-to-moderate AA [39]. One, two and three allergens 
were prescribed in 82, 8 and 6  % of cases, respectively 
(with missing data in 4  %). One year of SLIT was asso-
ciated with significant reductions in ocular, nasal, and 
bronchial symptom scores (p < 0.01) and rescue medica-
tion use (p < 0.01), relative to pre-treatment values [39].
Hence, in surveys of real-life clinical practice, allergy 
specialists appear to consider that polysensitization per 
se does not influence the indications for AIT [12, 35, 40]. 
One should remind that the interpretation of adverse 
reactions maybe challenging: the culprit allergen is diffi-
cult to identify when a mixture is administered.
Although prescribing AIT in polysensitized patients 
(who may be monoallergic or polyallergic) is not a prob-
lem for trained clinicians with experience in allergy, the 
management approaches are not standardized and there 
is no clear-cut decision tree to assist clinicians in their 
provision of high-quality care. In general, the absence of 
clear guidelines and practice parameters has prompted 
physicians to shy away from prescribing AIT to polyal-
lergy patients.
A practice‑based approach
We asked the group the following questions and moved 
forward by consensus:
1. How can be a polyallergic patient be identified?
2. When is AIT with a single allergen source indicated?
3. When AIT is with two allergen sources indicated 
(mixtures or two parallel course of AIT)?
4. When should two allergen sources be administered 
concomitantly?
5. How should two allergen sources be administered 
sequentially?
6. Can SLIT be combined with SCIT for 2-allergen 
immunotherapy?
7. When is AIT with three or more allergen sources 
indicated?
8. Are there specific issues to be considered when treat-
ing the most frequent polyallergic profiles?
9. Are there any other specific considerations?
How can be a polyallergic patient be identified?
Two main diagnostic methods are at our disposal: SPTs 
and ssIgE assays, both of which can only demonstrate the 
patient’s sensitization to an allergen source. These results 
must be cross-correlated with the clinician’s clinical 
interpretation, so as to identify the allergen(s) associated 
with a clinical and QoL impact (based on the GA2LEN 
recommendations) [23].
Although allergen challenges (i.e. a nasal challenge, a 
conjunctival challenge or exposure in a challenge cham-
ber) can reproducibly demonstrate the clinical relevance 
of a given sensitization, they are difficult to perform [41]. 
Furthermore, the SPT wheal diameter and ssIgE titre are 
of limited value for identifying clinically relevant causal 
allergens at the patient level, although they are very use-
ful at the population level [42]. In contrast, component 
resolved diagnosis (CRD) may help the physician to 
identify clinically relevant causal allergens and to distin-
guish genuine polysensitization (“co-sensitization”) from 
polysensitization due to cross-reactivity (“cross-sensitiza-
tion”) (Table 1). It is now clear that molecular diagnosis 
can help to tailor the individual AIT [43–48], and it was 
recently shown that the levels of ssIgE against Par j 2 and 
Bet v 1 may distinguish between sensitization and allergy 
[49, 50]. Furthermore, it has been reported that ssIgE lev-
els may predict the clinical response to AIT [51–53].
In particular, it is important to identify the allergen 
source(s) which most impact(s) QoL when allergies to 
two or more allergens from different homologous groups 
are diagnosed (e.g. grass pollen  +  HDM). Polyallergic 
patients will necessarily be polysensitized; the physician’s 
key task is to establish which of the sensitizing allergens 
are relevant with regard to the clinical symptoms of 
allergy. We consider that a patient’s clinical history alone 
is often (but not always) enough to identify the clinically 
relevant allergen in allergic respiratory disease, although 
it remains sufficient for an aetiological diagnosis in most 
cases. By way of an example, Crobach et al. reported that 
when considering a diagnosis of AR, the predictive value 
of the clinical history alone was 82–85  % for seasonal 
allergens and at least 77  % for perennial allergens [54]. 
These values increased to 97–99  % when both SPT and 
ssIgE data were available for a given patient.
Following identification of the most clinically relevant 
allergen, the physician’s next decision is how to treat the 
polyallergic patient.
When is AIT with a single allergen source indicated?
Single-AIT is recommended in polyallergic patients 
in whom one of several relevant allergens is neverthe-
less clearly responsible for the most intense and/or 
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bothersome symptoms. Again, the physician should 
identify this allergen on the basis of symptom intensity, 
impact on QoL, the duration of symptoms, and the ability 
to avoid allergens [23]. To facilitate the physician’s task, 
we have developed a treatment decision tree (Fig.  1). 
When selecting a treatment, patient preferences in rela-
tion to the administration route, adherence and cost, and 
the availability of high-quality AIT formulations must be 
taken into account.
Within a homologous group (such as Dermatopha-
goides species, Pooideae pollens or Betulaceae pollens), 
the use of a single course of AIT with a mixture of aller-
gens that mimics natural exposure is recommended (e.g. 
a Dermatophagoides pteronyssinus/Dermatophagoides 
farinae mixture, a grass mixture or a birch/hazel/nut 
mixture). Patients are exposed and sensitized to aller-
gen isoforms originating from two or more species in 
the group, and thus patients develop antibody and T cell 
responses to both cross-reactive (conserved) and non-
cross-reactive (species-specific) epitopes. Therefore, 
a mixture of both species provides a broad spectrum 
of allergens and thus B and T cell epitopes for optimal 
reprogramming of the immune system [55].
Sublingual immunotherapy with one or several extracts 
was safe and effective in improving allergy-related out-
comes [40, 56–61] (including a global asthma score, an 
YESNO
Patients with symptoms of allergic conjunctivitis and/or rhinitis and/or mild to moderate asthma
Patients with symptoms of hypersensitivity to hymenoptera venom
POLYSENSITIZEDMONOSENSITIZED
“What is the sensizaon status? 
(SPT, ssIgE, CRD, paent interview)
How many allergens are clinically relevant?
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Fig. 1 Suggested algorithm for AIT in polyallergic patients
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asthma medication consumption score [59] and a health-
related QoL score [56]) in both children [39] and adults 
aged 50 and over [58].
When is AIT with two allergen sources indicated (mixtures or 
two parallel courses of AIT)?
Parallel 2-allergen immunotherapy or mixed 2-aller-
gen immunotherapy is indicated in polyallergic patients 
in whom two causal relevant allergens have a marked 
clinical and QoL impact. Our recommendations for the 
choice of AIT modality as a function of the clinically 
relevant allergen are summarized in Table  3. Treatment 
adherence and cost are both issues that may influence 
the physician’s decision to prescribe 2-allergen immu-
notherapy rather than a mixture. Should 2-allergen 
immunotherapy be indicated, it should preferably be 
administered as two standardized, single-AIT formula-
tions in parallel (see below). Mixing of allergen extracts 
may be considered, as long as (1) the mixture is techni-
cally feasible (according to good manufacturing practice), 
(2) the mixture is allowed from a regulatory standpoint, 
(3) the various components are present at a concentration 
for which efficacy has been clearly demonstrated, and (4) 
the individual allergen doses in a mixture are adjusted 
(e.g. 1/2 of allergen source 1 and 1/2 of allergen source 2 
in a two-allergen source mixture; 1/3 of allergen source 
1, 1/3 of allergen source 2 and 1/3 of allergen source 3 
in a three-allergen source mixture, etc). There is no sci-
entific rationale for adjusting the mixing ratio mixture 
as a function of diagnostic test results, since the latter 
are not linked to clinical manifestations. However, mix-
ing several allergen extracts is associated with a risk of 
(1) proteolytic degradation (as mentioned by the EMA) 
and (2) possible antigenic competition, due to saturation 
of the immune system’s allergen processing pathways at 
the administration site [24, 28, 62]. Although the latter 
subject requires further study, it has been reported that 
antigenic competition affects the immunogenicity and 
efficacy of injectable paediatric vaccines with antigens 
from six infectious pathogens [63].
















Birch group or 
fagales group’
1 AIT 
2 AIT and/or 
mixtures
2 AIT and/or 
mixtures
2 AIT and/or 
mixtures
2 AIT and/or 
mixtures
2 AIT 2 AIT 2 AIT 2 AIT 
Oleaceae
2 AIT and/or 
mixtures
1 AIT 
2 AIT and/or 
mixtures
2 AIT and/or 
mixtures
2 AIT and/or 
mixtures
2 AIT 2 AIT 2 AIT 2 AIT 
Cupressaceae
2 AIT and/or 
mixtures
2 AIT and/or 
mixtures
1 AIT 
2 AIT and/or 
mixtures
2 AIT and/or 
mixtures
2 AIT 2 AIT 2 AIT 2 AIT 
Grasses  and 
cereal 
(Pooideae)
2 AIT and/or 
mixtures
2 AIT and/or 
mixtures
2 AIT and/or 
mixtures
1 AIT 
2 AIT and/or 
mixtures
2 AIT 2 AIT 2 AIT 2 AIT 
Weed pollen
2 AIT and/or 
mixtures
2 AIT and/or 
mixtures
2 AIT and/or 
mixtures
2 AIT and/or 
mixtures
1 AIT 2 AIT 2 AIT 2 AIT 2 AIT 
Mites (different 
sources )
2 AIT 2 AIT 2 AIT 2 AIT 2 AIT 2 AIT and/or mixtures 2 AIT 2 AIT 2 AIT 
Venom 2 AIT 2 AIT 2 AIT 2 AIT 2 AIT 2 AIT 2 AIT 2 AIT 2 AIT 
Danders 2 AIT 2 AIT 2 AIT 2 AIT 2 AIT 2 AIT 2 AIT 2 AIT 2 AIT 
Moulds 2 AIT 2 AIT 2 AIT 2 AIT 2 AIT 2 AIT 2 AIT 2 AIT 2 AIT 
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Good adherence is a prerequisite for efficacy (regard-
less of the type of medication, and notably for AIT [64]), 
and so increasing the complexity of the treatment regi-
men will accentuate the importance of this parameter 
[65]. Likewise, two parallel courses of AIT will neces-
sarily increase the cost of the treatments and associated 
procedures. Hence, cost and adherence issues may some-
times mean that two parallel courses of AIT are not 
indicated in a particular polyallergic patient; in some cir-
cumstances, a mixture might be an appropriate option.
How should two allergen sources be administered 
concomitantly?
Two-allergen immunotherapy can be administered as 
(1) a single mixture of two extracts (mixed multi-AIT, 
Table 1), with the standard ratio of each allergen source, 
or (2) two separate but simultaneous courses of one-aller-
gen immunotherapy (parallel multi-AIT, Table 1). Use of 
separate AIT formulations is preferable when treating 
with two non-homologous allergens (as defined by the 
EMA). Most cases of polyallergy requiring the simulta-
neous administration of two clinically relevant allergens 
will involve non-homologous allergens (such as grass pol-
len + HDMs), rather than homologous allergens (such as 
olive pollen and ash pollen).
For SLIT (given its excellent safety profile), we recom-
mend administering two separate SLIT formulations in 
the morning with an interval of 30 min (or one in the 
morning and one later on in the day). Although there 
may be an immune saturation effect at the oral mucosa 
[24, 62], this potential issue is avoided by ensuring an 
interval of 30 min between administrations of SLIT for-
mulations. For SCIT, quasi-simultaneous injections at 
different sites/arms are commonly used by some experi-
enced practitioners. However, the recommended 30-min 
observation period after each injection remains essential 
as a way of determining the responsibility of a particular 
allergen extract if adverse events occur.
There are few robust studies on the efficacy of mixed 
multi-AIT vs. parallel multi-AIT or on parallel vs. 
sequential administration [30]. Despite the absence of 
clinical trial results supporting the use of mixed aller-
gens, there are no immunological reasons why a 2-aller-
gen extract of homologous groups or two separate 
one-allergen extracts would lack efficacy.
When should two allergen sources be administered 
sequentially?
Allergen immunotherapy should be initiated first for 
the most clinically relevant allergen, then a subsequent 
course with the second more important allergen can be 
considered, at least 1 year after. Therefore we are speak-
ing of 6 years at most.
However, lack of good adherence is a problem with 
both SCIT and SLIT when considered in terms of com-
pleting courses of therapy.
Can SLIT be combined with SCIT for 2‑allergen 
immunotherapy?
A combination of SCIT and SLIT may be appropriate, 
subject to the patient’s preference and level of adherence, 
and the nature of the allergen source. For example, SCIT 
with a perennial allergen source and pre- and co-sea-
sonal SLIT with a seasonal allergen will reduce the over-
all number of administrations. Both SLIT and SCIT are 
safe and effective when correctly prescribed and appro-
priately administered. By analogy with single-AIT (see 
above), the physician and the patient will decide together 
on the most appropriate administration route, as a func-
tion of personal preference and the availability of high-
quality AIT formulations. However, if SLIT (or SCIT) is 
chosen because it is likely to be safe, effective and con-
venient for one course of treatment, it is likely to be so for 
a second course of treatment.
When is AIT with three or more allergen sources indicated?
We recommend focusing on the two most clinically rel-
evant allergen sources. Hence, AIT with three or more 
allergen sources should only be considered in the very 
rare cases in which (1) all the allergens clearly cause 
severe symptoms and (2) a definitive molecular diag-
nosis (with CRD) is available prior to initiation of AIT. 
Even then, the physician should consider very carefully 
whether sequential treatments with a single-allergen 
formulation or several single-allergen formulations in 
parallel (together with on-demand symptomatic medica-
tions) will in fact be enough to provide the patient with 
adequate symptom relief. If AIT with three or more aller-
gens is considered, its administration should follow the 
guidance given above for 2-allergen immunotherapy (i.e. 
administration at different times and body sites).
Prescriptions of AIT with three or more allergen 
sources are rare in European countries (and thus few data 
are available) but very common in the US [35]. In obser-
vational surveys in France, only 1.1  % of AIT prescrip-
tions contained three or more allergen sources [36]. If a 
mixture of three or more allergen sources has to be used, 
individual doses must be adapted as described above, and 
this is likely to impact efficacy.
Are there specific issues to be considered when treating the 
most frequent polyallergic profiles?
Based on our experience in our respective countries, 
the following patient profiles will be most commonly 
concerned by the present guidance. In Europe, grass 
pollen +  birch pollen is the most common polyallergic 
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profile, followed by pollens + HDM. In a study in France, 
the most frequent polyallergy combinations were grass 
pollen-HDM (16.9 %), grass pollen-tree pollens (12.2 %), 
HDM-dander (10.6 %), HDM-dander-grass pollen (9 %), 
and HDM-tree pollen-grass pollens (8.1  %), albeit with 
regional variations. 76 % of the polyallergic patients pre-
sented with both seasonal and perennial allergies, 13  % 
suffered from perennial allergies only and 11 % suffered 
from seasonal allergies only [36].
The most common combinations of allergies in Ger-
many are grass pollen + birch, grass pollen + HDMs, and 
tree pollen +  HDMs; one should be aware that in Ger-
many, mixing any other extract with a grass pollen, tree 
pollen or HDM extract would then mean that the result-
ing mixture becomes subject to the German Therapy 
Allergen Ordinance and thus would have to be approved 
by the regulatory authorities [66, 67]. In Italy, the most 
common combinations are grass pollen + HDMs, grass 
pollen +  Parietaria pollen; HDMs +  Parietaria pollen, 
grass pollen + birch pollen. In Spain, the most common 
combinations are grass pollen + olive pollen; grass pol-
len + Cupressus sp. pollen, Salsola pollen + grass pollen, 
Cupressus sp. pollen + olive pollen, grass pollen + Pari-
etaria pollen, Dermatophagoides sp. + Blomia tropicalis 
and Dermatophagoides sp. + Lepidoglyphus destructor.
Are there any other specific considerations?
The physician must consider allergens such as the mite 
Blomia tropicalis, the subtropical Chloridoideae sub-
family of grasses (e.g. Cynodon dactylon, Bermuda grass) 
and the Panicoideae subfamily of grasses (e.g. Paspalum 
notatum, Bahia grass)—especially for regional allergens 
or in (sub)tropical areas.
Ragweed pollen is a highly allergenic agent in some 
regions of Italy, France and eastern European countries.
Alternaria mould is also sometimes an issue (particu-
larly in Spain), and so more studies of mould allergies are 
needed. With regard to animal dander, there is concern 
as to whether the doses of allergens in extracts are suf-
ficiently high. Cockroaches and occupational allergens 
may be important in a few cases, although extracts are 
poorly standardized. In subtropical areas, the mite Blo-
mia tropicalis has clear clinical relevance, and cross-reac-
tivity with Dermatophagoides allergens is only partial. 
Cynodon dactylon may also be important and has limited 
cross-reactivity with the Pooideae [68]. These allergen 
sources deserve a thorough analysis of the literature and 
the provision of advice from experts in exposed areas.
Conclusions
We recommend single-AIT in (1) polyallergic patients 
with a seasonal allergy to one allergen source and per-
ennial allergy to another allergen, and (2) polyallergic 
patients in whom one of the several relevant allergens 
is clearly responsible for the most intense and/or both-
ersome symptoms. We recommended parallel or mixed 
2-allergen immunotherapy only for patients in whom 
two allergens have similar, significant clinical and QoL 
impacts that overlap in time. When prescribed, 2-aller-
gen immunotherapy should preferably consist of the sep-
arate administration of two high-quality, standardized, 
single-allergen formulations; this is highly preferable for 
non-homologous allergens. Simultaneous treatment with 
three or more allergens is rarely going to be clinically rel-
evant. If a mixture has to be used, there is no reason for 
varying the ratios between the individual allergen sources 
(e.g. one should always use 1/2 of allergen source 1 and 
1/2 of allergen source 2 in a two-allergen mixture; 1/3 
of allergen source 1, 1/3 of allergen source 2 and 1/3 of 
allergen source 3 in a three-allergen mixture, etc), while 
ensuring that each of the components is still present at a 
concentration for which efficacy has been clearly demon-
strated. All these preparations should used high-quality, 
evidence-supported and well standardized extracts as 
required by the World Allergy Organization [69].
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